COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma

Página do item simplificado
dc.creatorMarco Aurelio Petroni Montezuma
dc.creatorFelipe Paiva Fonseca
dc.creatorBernar Monteiro Benites
dc.creatorCiro Dantas Soares
dc.creatorGleyson Kleber do Amaral Silva
dc.creatorOslei Paes de Almeida
dc.creatorFernando Augusto Soares
dc.creatorRosana Lima Pagano
dc.creatorEduardo Rodrigues Fregnani
dc.date.accessioned2023-11-07T21:12:15Z
dc.date.accessioned2025-09-08T23:52:06Z
dc.date.available2023-11-07T21:12:15Z
dc.date.issued2018-06
dc.identifier.doihttps://doi.org/10.1016/j.prp.2018.03.014
dc.identifier.issn03440338
dc.identifier.urihttps://hdl.handle.net/1843/60618
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofPathology - Research and Practice
dc.rightsAcesso Restrito
dc.subjectAmeloblastoma
dc.subjectAntigens, CD34
dc.subjectOdontogenic tumors
dc.subjectCyclooxygenase 2
dc.subjectMicrovascular density
dc.subjectSurvival rate
dc.subject.otherbusca dia 21 do 09 ano 2023 fao clinica restrito assunto ameloblastoma
dc.titleCOX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma
dc.typeArtigo de periódico
local.citation.epage913
local.citation.issue6
local.citation.spage907
local.citation.volume214
local.description.resumoAmeloblastoma is a locally aggressive neoplasm with a poorly understood pathogenesis. Therefore, the aim of this study is to investigate whether COX-2 expression is associated with ameloblastoma microvascular density (MVD) and with tumor aggressiveness. Sixty-three cases of primary ameloblastomas arranged in tissue microarray were submitted to immunohistochemistry against cyclooxigenase-2 (COX-2) and CD34. Clinicopathological parameters regarding sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic features, vestibular/lingual and basal cortical disruption and follow-up data were obtained from patients' medical records and correlated with the proteins expression. The results on BRAF-V600E expression were obtained from our previous study and correlated with COX-2 and CD34 expressions. Log-rank univariate analysis and multivariate Cox regression model were done to investigate the prognostic potential of the molecular markers. Twenty-eight cases (44.4%) exhibited cytoplasmic positivity for COX-2, predominantly in the columnar peripheral cells, with a mean MVD of 2.2 vessels/mm2. COX-2 was significantly associated with recurrences (p < 0.001) and BRAF-V600E expression (p < 0.001), whereas lower MVD was associated with the use of conservative therapy (p = 0.004). Using univariate and multivariate analyses, COX-2 was significantly associated with a lower 5-year disease-free survival (DFS) rate (p < 0.001 and p = 0.012, respectively), but not with a higher MVD (p = 0.68). In conclusion, COX-2 expression in ameloblastomas is not associated with MVD, but it is significantly associated with recurrences and with a lower DFS.
local.publisher.countryBrasil
local.publisher.departmentFAO - DEPARTAMENTO DE CLÍNICA
local.publisher.initialsUFMG
local.url.externahttps://www.sciencedirect.com/science/article/pii/S034403381830092X?via%3Dihub

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG